US03528H1095
© PR Newswire
12.12.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
News Preview
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated DoseResults Support Advancement of the Program into Phase 2 DevelopmentCombination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patientsSA...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
News Preview
SAN JOSE, Calif., Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Monday, D...
Themefolio
Profiler
Peergroup
© PR Newswire
17.11.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
News Preview
SAN JOSE, Calif., Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) ap...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
12.11.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
News Preview
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026
SAN JOSE, Calif., Nov. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focuse...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
10.11.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
News Preview
SAN JOSE, Calif., Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Ch...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
News Preview
Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial
SAN JOSE, Calif., Nov. 5, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment an...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
News Preview
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in China into 2040
SAN JOSE, Calif., Oct. 20, 2025 /PRNe...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
ANIX
LISTED
NASDAQ
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
ANIX
LISTED
NASDAQ
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 8, 2025 /CNW/ -- Ohio...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
ANIX
LISTED
NASDAQ
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
News Preview
Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine
Comprehensive Immune Response and Safety Data to Be Presented at the San Antonio Breast Cancer Symposium in December...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ANIX
LISTED
NASDAQ
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
News Preview
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention
Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance Phase 2 Development Plans
SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
16.09.2025
ANIX
LISTED
NASDAQ
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumo...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ANIX
LISTED
NASDAQ
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /CNW/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumor elimi...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ANIX
LISTED
NASDAQ
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumo...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
SAN JOSE, Calif., Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the time of management's presentation at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8th – 10th, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
SAN JOSE, Calif., Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8th – 10th, 2025 at the...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
News Preview
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s
SAN JOSE, Calif., Aug. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
News Preview
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045
SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (U...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
News Preview
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program a...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
News Preview
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform
Expands Global IP Coverage in Markets with High Incidence of Breast Cancer
SAN JOSE, Calif., July 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of...
Themefolio
Profiler
Peergroup
© PR Newswire
24.07.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
News Preview
Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform
Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential
SAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatmen...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
News Preview
SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of it...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
News Preview
Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose
SAN JOSE, Calif., June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in...
Themefolio
Profiler
Peergroup
© PR Newswire
20.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
News Preview
SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT....
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ANIX
LISTED
NASDAQ
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ANIX
LISTED
NASDAQ
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in AI, di...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
ANIX
LISTED
NASDAQ
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
News Preview
SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
News Preview
SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clini...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
News Preview
SAN JOSE, Calif., June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine. The segment...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
News Preview
SAN JOSE, Calif., June 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is a...
Themefolio
Profiler
Peergroup
© PR Newswire
19.05.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
News Preview
SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit Kumar, detailing significant progress across its programs and outlining key milestones f...
Themefolio
Profiler
Peergroup
© PR Newswire
12.05.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
News Preview
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual M...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
News Preview
SAN JOSE, Calif., April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025, at Nasdaq World Headquarters...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
News Preview
SAN JOSE, Calif., April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering i...
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
News Preview
Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach
SAN JOSE, Calif., April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
News Preview
SAN JOSE, Calif., April 1, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025, at The Venetian Resor...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
News Preview
VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients
SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI...
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
News Preview
SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
News Preview
SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") Ne...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
News Preview
SAN JOSE, Calif., March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
News Preview
SAN JOSE, Calif., March 3, 2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Pam Garzone, Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
News Preview
SAN JOSE, Calif., Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
News Preview
SAN JOSE, Calif., Feb. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its breast cancer vaccine was featured on Fox News' "America Reports." The segment highlighted the potential of Anixa's vaccine to revolu...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
News Preview
SAN JOSE, Calif., Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prom...
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
News Preview
Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies
SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along w...
Themefolio
Profiler
Peergroup
© PR Newswire
11.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum
News Preview
SAN JOSE, Calif., Feb. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Mike Catelani, President and CFO of Anixa, will be participating in the 18th Annual European Life Sciences CEO Forum taking place Februar...
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention
News Preview
SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, was featured on CW39's H-Town Live, where he discussed the Company's pioneering efforts in brea...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences CEO Provides Letter to Shareholders
News Preview
SAN JOSE, Calif., Jan. 21, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided the following letter to shareholders from the Company's, Chairman and CEO, Dr. Amit Kumar:...
Themefolio
Profiler
Peergroup
© PR Newswire
22.11.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
News Preview
SAN JOSE, Calif., Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset....
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
News Preview
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose
SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the t...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
Data continues positive trend as additional patients are enrolled in 3 cohortsVaccine was safe and well tolerated by participants in all 3 cohortsProtocol defined immune responses were exhibited in over 70% of patientsA Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025SAN JOSE, Calif., Nov. 8, 2024 /PR...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
SAN JOSE, Calif., Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cance...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
News Preview
SAN JOSE, Calif., Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024. Anixa Chairman and CEO Dr. Amit Kumar will pre...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SIT...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
News Preview
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose
SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
News Preview
SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone,...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
News Preview
Amendment will allow a second dose of CAR-T therapy to suitable patients
SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner Moffitt Cancer Center ("Moffitt") have submitted...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
ANIX
LISTED
NASDAQ
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
News Preview
Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval
SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 stud...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
